Analysis of post-study chemotherapy in patients (pts) enrolled in the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for Dukes' C colon cancer: No differences in treatment arms that could influence survival outcome.

被引：0
|
作者：
Cassidy, J
Koralewski, P
Husseini, F
Twelves, C
机构：
[1] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland
[2] Rydygier Mem Hosp, Krakow, Poland
[3] Hop Civils Colmar, Colmar, France
[4] Univ Leeds, Bradford, W Yorkshire, England
[5] Bradford NHS Hosp Trust, Bradford, W Yorkshire, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：267S / 267S
页数：1
相关论文
共 27 条
  • [21] First efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study)
    Hailer, D.
    Tabernero, J.
    Maroun, J.
    de Braud, F.
    Price, T.
    Van Cutsem, E.
    Hill, M.
    Gilberg, F.
    Rittweger, K.
    Schmoll, H.
    EJC SUPPLEMENTS, 2009, 7 (03): : 4 - 4
  • [22] RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): IMPACT OF AGE ON DISEASE-FREE SURVIVAL (DFS) OR OVERALL SURVIVAL (OS)
    Haller, D.
    Cassidy, J.
    Tabernero, J.
    Maroun, J. A.
    De Braud, F.
    Price, T. J.
    van Cutsem, E.
    Hill, M.
    Gilberg, F.
    Schmoll, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 207 - 207
  • [23] EFFICACY FINDINGS FROM A RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): NO IMPACT OF AGE ON DISEASE-FREE SURVIVAL
    Haller, D.
    Cassidy, J.
    Tabernero, J.
    Maroun, J.
    De Braud, F.
    Price, T.
    Van Cutsem, E.
    Hill, M.
    Gilberg, F.
    Schmoll, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [24] TP, TS AND DPD AS POTENTIAL PREDICTORS OF OUTCOME FOLLOWING CAPECITABINE PLUS OXALIPLATIN (XELOX) VS. BOLUS 5-FLUOROURACIL/LEUCOVORIN (5-FU/LV) AS ADJUVANT THERAPY FOR STAGE III COLON CANCER: UPDATED BIOMARKER FINDINGS FROM STUDY NO16968 (XELOXA)
    Schmoll, H.
    Tabernero, J.
    Maroun, J. A.
    De Braud, F.
    Price, T.
    Van Cutsem, E.
    Hill, M.
    Hoersch, S.
    Rittweger, K.
    Haller, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 187 - 187
  • [25] Initial safety findings from a phase III study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC)
    Bennouna, J.
    Liedo, G.
    Ychou, M.
    Conroy, T.
    Hebbar, M.
    Adenis, A.
    Paillot, B.
    Faroux, R.
    Douillard, J.
    Ducreux, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 179 - 180
  • [26] Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis.
    Ducreux, M
    Adenis, A
    Bennouna, J
    Conroy, T
    Faroux, R
    Hebbar, M
    Lledo, G
    Paillot, B
    Ychou, M
    Douillard, JY
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 270S - 270S
  • [27] Phase III, randomized study of docetaxel (T) plus capecitabine (X) (TX) followed by cyclophosphamide (C) plus epirubicin (E) plus X (CEX) vs. T followed by C plus E plus fluorouracil (F) (CEF) as adjuvant treatment for patients (pts) with early breast cancer (BC): An interim safety analysis.
    Joensuu, H
    Hemminki, A
    Tanner, M
    Paija, O
    Kokko, R
    Asola, R
    Johansson, K
    Bono, P
    Elomaa, I
    Kellokumpu-Lehtinen, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 57S - 57S
123